EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study

Gianvito Barbella iD, Pietro Antenucci iD, Vittorio Govoni iD, Ilaria Casetta iD, Maurizio Paciaroni iD, Marina Padroni iD

Journal of Ultrasonography · 30.06.2026 · 26 (105)

DOI: 10.15557/jou.2026.0016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ultrasonography, online erschienen am 30.06.2026. Verfasst von Gianvito Barbella und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences and Rehabilitation, University of Ferrara,Italy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Migraine is the second most disabling condition worldwide. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway represent an effective prophylactic treatment; however, their impact on cerebral hemodynamics remains unclear. The aim of this pilot study was to evaluate cerebrovas- cular risk in patients with migraine without aura treated with these therapies, by calculating the breath-holding index (BHI) of the anterior cerebral circulation using transcranial color-coded Doppler (TCCD) ultrasonography. Material and methods: Cerebral vasomotor reactivity to hypercapnia was assessed using the breath-holding test combined with TCCD ultrasonography in 40 patients with migraine without aura undergoing treatment with anti-CGRP monoclonal antibodies and 40 healthy subjects. BHI values and other key cerebrovascular parameters were compared between the groups.

Results

The BHI values in patients with migraine without aura were not below the threshold predictive of increased cerebrovascular risk (less than 0.69% per second, as referenced in the general population). No significant differences were observed in major cerebrovascular parameters between cases and controls. Additionally, a subanalysis revealed no significant differences based on the specific monoclonal antibody (erenumab, fremanezumab, or galcanezumab) or clinical response status (responders versus non-responders).

Conclusions

Our findings suggest that treatment with anti-CGRP monoclonal antibodies is not associated with a BHI indicative of increased cerebrovascular risk. Notably, this is the first study to include galcanezumab and fremanezumab in the evaluation of cerebrovascular risk using ultrasound, highlighting TCCD ultrasonography as a practical and non-invasive tool for the assessment of cerebrovascular reactivity in migraine.

Schlagwörter

Stichwörter der Autor:innen

anti-CGRPmigrainemonoclonal antibodiestranscranial ultrasoundvasomotor reactivity

Autor:innen und Institutionen

  • Department of Neurosciences and Rehabilitation, University of Ferrara,Italy.
  • Department of Neurology, IRCCS San Camillo Hospital, Venice, Italy.
  • Department of Neurology Unit, Ferrara University Hospital,Italy.

ORCID-Profile: Gianvito Barbella, Pietro Antenucci, Vittorio Govoni, Ilaria Casetta, Maurizio Paciaroni, Marina Padroni

Zitieren

APA

Barbella, G., Antenucci, P., Govoni, V., Casetta, I., Paciaroni, M., & Padroni, M. (2026). Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. Journal of Ultrasonography, 26(105). https://doi.org/10.15557/jou.2026.0016

Vancouver

Barbella G, Antenucci P, Govoni V, Casetta I, Paciaroni M, Padroni M. Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. Journal of Ultrasonography. 2026;26(105). doi:10.15557/jou.2026.0016

BibTeX
@article{Barbella2026,
  author = {Barbella, Gianvito and Antenucci, Pietro and Govoni, Vittorio and Casetta, Ilaria and Paciaroni, Maurizio and Padroni, Marina},
  title = {Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study},
  journal = {Journal of Ultrasonography},
  year = {2026},
  volume = {26},
  number = {105},
  doi = {10.15557/jou.2026.0016}
}
Kostenlos starten →